<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670810</url>
  </required_header>
  <id_info>
    <org_study_id>17131</org_study_id>
    <secondary_id>H8H-MC-LAIJ</secondary_id>
    <secondary_id>2018-001661-17</secondary_id>
    <nct_id>NCT03670810</nct_id>
  </id_info>
  <brief_title>A Study of Lasmiditan (LY573144) Over Four Migraine Attacks</brief_title>
  <official_title>Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The reason for this study is to see how effective and safe the study drug known as lasmiditan&#xD;
      is in the acute treatment of 4 migraine attacks with or without aura.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 24, 2019</start_date>
  <completion_date type="Actual">July 8, 2021</completion_date>
  <primary_completion_date type="Actual">June 12, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>To evaluate the 2 out of 3 primary consistency endpoint, the results of ITT evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT evaluable attacks, only the first 3 will be considered. Pain-free was defined as mild, moderate, or severe headache pain becoming none at the indicated assessment time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pain Relief at 2 Hours Post Dose During the First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 2 Out of 3 Attacks</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Headache pain relief is defined as a reduction in pain severity from moderate to severe at baseline to mild or none at 2 hours postdose in at least 2 out of 3 attacks. To evaluate at least 2 out of 3 consistency endpoints, the results of ITT-evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT-evaluable attacks, only the first 3 with the same treatment will be considered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 24-Hour Sustained Pain Freedom During the First Attack</measure>
    <time_frame>24 Hours</time_frame>
    <description>Sustained pain freedom defined as pain free at 2 and 24 hours with no rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With 48-Hour Sustained Pain Freedom During First Attack</measure>
    <time_frame>48 Hours Postdose</time_frame>
    <description>Sustained pain freedom defined as pain free at 2 and 48 hours with no rescue medication.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack in Triptan Insufficient Responders.</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack. A triptan insufficient responder is defined as having one of the following: 1) Scoring â‰¤5 on 4 questions from the Migraine Treatment Optimization Questionnaire (mTOQ-6) that defines participants with poor or very poor response to their current regimen; 2) Indicated they obtained pain freedom at 2 hours in 0 out of 3, or 1 out of 3 attacks when treated with the most recent triptan, or 3) are not currently taking triptan and discontinued their most recent triptan due to lack of efficacy, tolerability issue, or contradictions to a past triptan.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With no Disability as Measured by the Disability Item, at 2 Hours Postdose During the First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of participants with no disability as measured by the disability item, at 2 hours postdose during the first attack. Disability was measured by determining the level of interference with normal activities with 4 response options including not at all; mild interference, marked interference; and need complete bed rest.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks in Triptan Insufficient Responders</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at the indicated assessment time. A subject is not counted as being pain-free at a specific time point if she or he used rescue or recurrence medication at or before the specific time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Free of Most Bothersome Symptom (MBS) Associated With Migraine at 2 Hours Postdose During the First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>MBS freedom is defined as the absence of the associated symptom of migraine (nausea, phonophobia, or photophobia) at the indicated assessment time that was identified at baseline as the most bothersome symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Requiring Rescue Medication for Migraine Within 24 Hours of Treatment During the First Attack</measure>
    <time_frame>24 Hours</time_frame>
    <description>Percentage of participants requiring rescue medication for migraine within 2 to 24 hours of treatment during the first attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Are Free of Symptoms Associated With Migraine at 2 Hours Postdose During the First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Percentage of participants that are free of symptoms associated with migraine (photophobia, phonophobia, nausea, and vomiting) at 2 hours postdose during the first attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Migraine Recurrence at 24 Hours During the First Attack</measure>
    <time_frame>24 Hours</time_frame>
    <description>Percentage of participants with migraine recurrence at 24 hours during the first attack defined as return of any headache in participants who were pain free at 2 hours.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pain Freedom, Pain Relief, Freedom From MBS, and No Disability Postdose During First Attack</measure>
    <time_frame>30 Minutes (Min) and 1 Hour (Hr) Postdose</time_frame>
    <description>Percentage of participants with pain freedom, pain relief, freedom from MBS, and no disability postdose during first attack.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Total Score as Measured by the Migraine Disability Assessment Test (MIDAS) Scale</measure>
    <time_frame>Baseline, Week 16</time_frame>
    <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of 5 items that reflect the number of days reported as missed, or with reduced productivity at work or home and social events. Each question is answered as the number of days during the past 3 months of assessment, ranging from 0 to 90, with the total score being the summation of the 5 numeric responses. A higher value is indicative of more disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Very Much or Much Better as Measured by Patient Global Impression of Change (PGI-C), at 2 Hours Postdose During the First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>The PGI-C is a one-item questionnaire that asks participants to provide their impression of change since taking the medicine. The PGI-C is measured using a 7-point Likert scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Reported are participants whose combined impression of change since taking the medicine was very much better and much better at 2 hours postdose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Migraine Quality of Life Questionnaire (MQoLQ) Score at 24 Hours Post First Dose of Study During First Attack</measure>
    <time_frame>24 Hours Post First Dose</time_frame>
    <description>The 24-hour Migraine Quality of Life Questionnaire (24-hr MQoLQ) has been specifically developed to measure the HRQoL of participants with migraine within a 24-hour period after having taken migraine medication A domain score is calculated by summing the responses to the 3 questions and the domain score ranges from 3 to 21, with lower scores indicating less impairment. The questionnaire will be administered 24 hours after dosing with study drug during each migraine. The analysis of variance (ANOVA) model was used with region and treatment adjusted for the overall treatment effect.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Satisfied With Their Treatment Measured by a 4-Item Questionnaire</measure>
    <time_frame>Week 16</time_frame>
    <description>Treatment satisfaction was evaluated at the End of Study (EoS) visit by determining the participant's level of satisfaction (ranging from extremely dissatisfied to extremely satisfied); their willingness to take this treatment again (ranging from strongly disagree to strongly agree) and if they would they recommend this treatment to another participants (ranging from strongly disagree to strongly agree).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Utility at 24 Hours Postdose as Measured by the EuroQol 5-Dimension 5-Level Scale (EQ-5D-5L) at 24 Hours Postdose During First Attack</measure>
    <time_frame>Baseline, 24 Hours Postdose</time_frame>
    <description>The EQ-5D-5L questionnaire is a participant-rated scale that assesses health status, it consists of 2 parts. The first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 possible levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems).The EQ-5D can be used to generate a health state index score, which is used to compute quality-adjusted life years for utilization in health economic analyses. The health state index score is calculated based on the responses to the 5 dimensions, providing a single value on a scale from less than 0 (where 0 is a health state equivalent to death) to 1 (perfect health), with higher scores indicating better health utility. ANCOVA was used to assess the effect of Lasmiditan over placebo or control. The model includes fixed categorical effect of treatment and geographic region and baseline as covariate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 3 Out of 4 Attacks</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe to none at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 3 Out of 4 Attacks</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Associated Migraines Symptoms of Nausea, Vomiting, Photophobia, and Phonophobia Present at 2 Hours Postdose for First Attack</measure>
    <time_frame>2 Hours Postdose</time_frame>
    <description>Presence of associated migraine symptoms at 2 hours postdose at first migraine attack, including each of the following: phonophobia, photophobia, nausea, and vomiting.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">1806</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>100 milligram (mg) Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Lasmiditan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 1 Sequence</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 2 Sequence</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.&#xD;
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100 mg Lasmiditan Maximum Extended Enrollment (MEE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg Lasmiditan MEE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 1 Sequence MEE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control 2 Sequence MEE</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 4.&#xD;
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lasmiditan</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>100 mg Lasmiditan Maximum Extended Enrollment (MEE)</arm_group_label>
    <arm_group_label>100 milligram (mg) Lasmiditan</arm_group_label>
    <arm_group_label>200 mg Lasmiditan</arm_group_label>
    <arm_group_label>200 mg Lasmiditan MEE</arm_group_label>
    <arm_group_label>Control 1 Sequence</arm_group_label>
    <arm_group_label>Control 1 Sequence MEE</arm_group_label>
    <arm_group_label>Control 2 Sequence</arm_group_label>
    <arm_group_label>Control 2 Sequence MEE</arm_group_label>
    <other_name>LY573144</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>100 mg Lasmiditan Maximum Extended Enrollment (MEE)</arm_group_label>
    <arm_group_label>100 milligram (mg) Lasmiditan</arm_group_label>
    <arm_group_label>200 mg Lasmiditan</arm_group_label>
    <arm_group_label>200 mg Lasmiditan MEE</arm_group_label>
    <arm_group_label>Control 1 Sequence</arm_group_label>
    <arm_group_label>Control 1 Sequence MEE</arm_group_label>
    <arm_group_label>Control 2 Sequence</arm_group_label>
    <arm_group_label>Control 2 Sequence MEE</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Migraine with or without aura fulfilling the International Headache Society (IHS)&#xD;
             diagnostic criteria 1.1 and 1.2.1&#xD;
&#xD;
          -  History of disabling migraine for at least 1 year&#xD;
&#xD;
          -  Migraine onset before the age of 50 years&#xD;
&#xD;
          -  History of 3 to 8 migraine attacks per month (&lt;15 headache days per month) during the&#xD;
             past 3 months&#xD;
&#xD;
          -  MIDAS score â‰¥11&#xD;
&#xD;
          -  Able and willing to complete an eDiary to record the details of each migraine attack&#xD;
             treated with study drug&#xD;
&#xD;
          -  Women of child-bearing potential must be using or willing to use a highly effective&#xD;
             form of contraception&#xD;
&#xD;
          -  Agree not to post any personal medical data or information related to the study on any&#xD;
             website or social media site until the entire trial has completed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity to lasmiditan, or to any excipient of lasmiditan oral tablets&#xD;
&#xD;
          -  History or evidence of hemorrhagic stroke, epilepsy, or any other condition placing&#xD;
             the participant at increased risk of seizures&#xD;
&#xD;
          -  History of recurrent dizziness and/or vertigo including benign paroxysmal positional&#xD;
             vertigo, Meniere's disease, vestibular migraine, and other vestibular disorders&#xD;
&#xD;
          -  History of diabetes mellitus with complications (diabetic retinopathy, nephropathy, or&#xD;
             neuropathy)&#xD;
&#xD;
          -  History of orthostatic hypotension with syncope&#xD;
&#xD;
          -  Significant renal or hepatic impairment in the opinion of the investigator or if they&#xD;
             meet hepatic monitoring criteria&#xD;
&#xD;
          -  Participants who, in the investigator's judgment, are actively suicidal and therefore&#xD;
             deemed to be at significant risk for suicide&#xD;
&#xD;
          -  History, within past 12 months, of chronic migraine or other forms of primary or&#xD;
             secondary chronic headache disorder (eg, hemicranias continua, medication overuse&#xD;
             headache where headache frequency is â‰¥15 headache days per month)&#xD;
&#xD;
          -  Use of more than 3 doses per month of either opioids or barbiturates&#xD;
&#xD;
          -  Initiation of or a change in concomitant medication to reduce the frequency of&#xD;
             migraine episodes within 3 months prior to screening&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  History of drug or alcohol abuse/dependence within 1 year prior to screening&#xD;
&#xD;
          -  Any medical condition or clinical laboratory test which in the judgment of the&#xD;
             investigator makes the participant unsuitable for the study&#xD;
&#xD;
          -  Currently enrolled in any other clinical study involving an investigational product&#xD;
&#xD;
          -  Relatives of, or staff directly reporting to, the Investigator&#xD;
&#xD;
          -  Participants who are employees of the sponsor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rehabilitation &amp; Neurological Services LLC</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Altman Clinical &amp; Translational Research Institute (ACTRI)</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Neurological Institute</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diamond Headache Clinic</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Medical Center - North Shore</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>StudyMetrix Research, LLC</name>
      <address>
        <city>Saint Peters</city>
        <state>Missouri</state>
        <zip>63303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nevada Headache Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113-2237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dent Neurological Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Headache Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Neuro Associates,PC</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007-4209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH der Barmherzigen Schwestern Linz BetriebsGesmbH</name>
      <address>
        <city>Linz</city>
        <state>OberÃ¶sterreich</state>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tirol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christian-Doppler-Klinik</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKH</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessa Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algemeen Ziekenhuis St Jan Brugge</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>B-9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC MontLÃ©gia</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valdor - ISOSL CCV - Clinique des cÃ©phalÃ©es du Valdor - Neurology</name>
      <address>
        <city>Liege</city>
        <zip>4020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital Affiliated to Capital Medical Univ</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xuanwu Hospital-Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <zip>400030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangzhou First People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510180</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Hong Kong-Shenzhen Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518053</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hebei General Hospital</name>
      <address>
        <city>ShiJiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First hospital affiliated to Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan Union (Xiehe) Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital, Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Zhenjiang</city>
        <state>Jiangsu</state>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Gannan Medical University</name>
      <address>
        <city>Ganzhou</city>
        <state>Jiangxi</state>
        <zip>341000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital</name>
      <address>
        <city>Pingxiang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No.2 Hospital Affiliated to Jilin University</name>
      <address>
        <city>Changchun City</city>
        <state>Jilin</state>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dalian Municipal Central Hospital Affiliated of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <state>Liaoning</state>
        <zip>116033</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Nanjing</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shengli Oilfield Central Hospital</name>
      <address>
        <city>Dongying</city>
        <state>Shandong</state>
        <zip>257034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's hospital of Rizhao</name>
      <address>
        <city>Rizhao</city>
        <state>Shandong</state>
        <zip>276826</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HuaShan Hospital Affiliated To Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>20040</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No 1 Affiliate Hospital of Kunming Medical College</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Wenzhou Medical College</name>
      <address>
        <city>WenZhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baotou Central Hospital</name>
      <address>
        <city>Baotou</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clintrial, s.r.o.</name>
      <address>
        <city>Praha 10</city>
        <state>Hl. M. Praha</state>
        <zip>100 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka ambulance, Neurologie Brno s.r.o.</name>
      <address>
        <city>Brno</city>
        <zip>616 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brain-Soultherapy s.r.o</name>
      <address>
        <city>Kladno</city>
        <zip>27201</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DADO MEDICAL, s.r.o.</name>
      <address>
        <city>Praha 2</city>
        <zip>120 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka ordinace</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologicka ambulance Prerov</name>
      <address>
        <city>Prerov</city>
        <zip>750 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR-Alborg-DK</name>
      <address>
        <city>Alborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Glostrup</city>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical and Basic Research -CCBR</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM HÃ´pital de la Timone</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois - Site d'Annecy</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital LariboisiÃ¨re</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Rouen Hopital Charles Nicolle</name>
      <address>
        <city>Rouen Cedex</city>
        <zip>76036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU St Etienne Hopital Nord</name>
      <address>
        <city>Saint Etienne Cedex 2</city>
        <zip>42000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60313</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DRK-Kliniken Nordhessen</name>
      <address>
        <city>Kassel</city>
        <state>Hessen</state>
        <zip>34121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis fÃ¼r Neurologie und Psychiatrie</name>
      <address>
        <city>Westerstede</city>
        <state>Niedersachsen</state>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. Philipp Stude</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DataMed Klinische Studien GmbH</name>
      <address>
        <city>KÃ¶ln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis fÃ¼r Neurologie und Psychiatrie</name>
      <address>
        <city>Essen</city>
        <state>North Rhine-Westphalia</state>
        <zip>45133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <state>ThÃ¼ringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CharitÃ© UniversitÃ¤tsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Clinical Research GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>12627</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Neurologische Praxis Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PANAKEIA - Arzneimittelforschung Leipzig GmbH</name>
      <address>
        <city>Leipzig</city>
        <zip>04275</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valeomed Kft.</name>
      <address>
        <city>Esztergom</city>
        <state>Komarom-Esztergom</state>
        <zip>2500</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SE Neurologiai Klinika</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orszagos Idegtudomanyi Intezet</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nizam's Institute of Medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Andhra Pradesh</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Apollo Hospitals International Ltd.</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>382428</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Artemis Hospital</name>
      <address>
        <city>Gurgaon</city>
        <state>Haryana</state>
        <zip>122001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M S Ramaiah Medical College Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mangala Hospitals &amp; Mangala Kidney Foundation</name>
      <address>
        <city>Mangalore</city>
        <state>Karnataka</state>
        <zip>575003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kokilaben Dhirubhai Ambani Hospital &amp;Medical Research Inst.</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400053</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCG Manavata Cancer Centre</name>
      <address>
        <city>Nasik</city>
        <state>Maharashtra</state>
        <zip>422001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deenanth Mangeshkar Hospital and Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411004</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gobind Ballabh Pant Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Ganga Ram Hospital</name>
      <address>
        <city>New Delhi</city>
        <zip>110060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Neuromed</name>
      <address>
        <city>Pozzilli</city>
        <state>Isernia</state>
        <zip>86077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Bellaria</name>
      <address>
        <city>Bologna</city>
        <zip>40139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Neurologico Carlo Besta</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Istituto Neurologico Nationale C. Mondino</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute S C</name>
      <address>
        <city>Tlalnepantla</city>
        <state>Edo De Mex</state>
        <zip>54055</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinstile, S.A de C.V</name>
      <address>
        <city>Cuauhtemoc</city>
        <state>Federal District</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CRI Centro Regiomontano de Investigacion S.C.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64060</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Care and Research, S.A. de C.V.</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97070</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Aplicadas a la Neurociencia A.C</name>
      <address>
        <city>Durango</city>
        <zip>34000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eci Estudios Clinicos Int.</name>
      <address>
        <city>Puebla</city>
        <zip>72160</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de AtenciÃ³n e InvestigaciÃ³n Cardiovascular del PotosÃ­ S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius-Wilhelmina Ziekenhuis</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6532 SZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boerhaave Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <zip>1078 VV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Klinieken</name>
      <address>
        <city>Zwolle</city>
        <zip>8025 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Moscow State Medical University n.a. Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Headache Clinic</name>
      <address>
        <city>Moscow</city>
        <zip>121467</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medis Priokskiy</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603137</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Petersburg State Medical University n.a. Pavlov I.P.</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques De Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria De Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital ClÃ­nico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valladolid</name>
      <address>
        <city>Valladolid</city>
        <zip>47010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H.C.U. Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern 16</city>
        <state>Luzern</state>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <state>Sankt Gallen</state>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KopfwehZentrum Hirslanden ZÃ¼rich</name>
      <address>
        <city>Zollikon</city>
        <state>Zurich</state>
        <zip>8702</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rehaclinic Bad Zurzach</name>
      <address>
        <city>Bad Zurzach</city>
        <zip>5330</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Thames Valley Clinical Research Centre</name>
      <address>
        <city>Reading</city>
        <state>Berkshire</state>
        <zip>RG2 0TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hull Royal Infirmary</name>
      <address>
        <city>Hull</city>
        <state>East Yorkshire</state>
        <zip>HU3 2JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kings College Hospital</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Re-Cognition Health Ltd</name>
      <address>
        <city>London</city>
        <state>Greater London</state>
        <zip>W1G 9JF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Manchester Clinical Research Centre</name>
      <address>
        <city>Manchester</city>
        <state>Greater Manchester</state>
        <zip>M15 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Lancashire Clinical Research Centre</name>
      <address>
        <city>Chorley</city>
        <state>Lancashire</state>
        <zip>PR7 7NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Merseyside Clinical Research Centre</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L22 0LG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Hexham General Hospital</name>
      <address>
        <city>Hexham</city>
        <state>Northumberland</state>
        <zip>NE46 1QJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth University Hospital</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Wales Clinical Research Centre</name>
      <address>
        <city>Cardiff</city>
        <state>South Glamorgan</state>
        <zip>CF15 9SS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Scotland Clinical Research Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Strathclyde</state>
        <zip>G20 0SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Re-Cognition Health Ltd</name>
      <address>
        <city>Guildford</city>
        <state>Surrey</state>
        <zip>GU2 7YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Re-Cognition Health Ltd</name>
      <address>
        <city>Birmingham</city>
        <state>West Midlands</state>
        <zip>B16 8LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Synexus Midlands Clinical Research Center</name>
      <address>
        <city>Birmingham</city>
        <state>Wstmid</state>
        <zip>B15 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Belgium</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/45cVxLjssEICmyC0uECUa4</url>
    <description>A Study of Lasmiditan (LY573144) Over Four Migraine Attacks</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 12, 2018</study_first_submitted>
  <study_first_submitted_qc>September 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2018</study_first_posted>
  <results_first_submitted>June 11, 2021</results_first_submitted>
  <results_first_submitted_qc>June 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 2, 2021</results_first_posted>
  <last_update_submitted>August 24, 2021</last_update_submitted>
  <last_update_submitted_qc>August 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>acute treatment</keyword>
  <keyword>migraine pain</keyword>
  <keyword>multiple attacks</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lasmiditan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>http://vivli.org/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03670810/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT03670810/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Participants were considered study completers after treating 4 migraine attacks or after completing 4 months of study duration regardless of number of treated attacks.&#xD;
An ITT evaluable attack is defined as a treated attack of least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.&#xD;
Results for maximum extended enrollment will be posted after the study completion.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>100 Milligram (mg) Lasmiditan</title>
          <description>Participants received one100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
        </group>
        <group group_id="P2">
          <title>200 mg Lasmiditan</title>
          <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind. Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
        </group>
        <group group_id="P3">
          <title>Control 1 Sequence</title>
          <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
        </group>
        <group group_id="P4">
          <title>Control 2 Sequence</title>
          <description>Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.&#xD;
Tablets were administered orally within 4 hours of onset of a single migraine attack, up to 4 migraine attacks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="485"/>
                <participants group_id="P2" count="486"/>
                <participants group_id="P3" count="249"/>
                <participants group_id="P4" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated at Least One Migraine Attack</title>
              <participants_list>
                <participants group_id="P1" count="485"/>
                <participants group_id="P2" count="486"/>
                <participants group_id="P3" count="249"/>
                <participants group_id="P4" count="251"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="381"/>
                <participants group_id="P2" count="369"/>
                <participants group_id="P3" count="208"/>
                <participants group_id="P4" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="104"/>
                <participants group_id="P2" count="117"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Continuing Study</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized participants who were treated with at least 1 dose of study drug, regardless of whether or not they undergo any study assessments.</population>
      <group_list>
        <group group_id="B1">
          <title>100 mg Lasmiditan</title>
          <description>Participants received 1-100 mg Lasmiditan tablet with 1-50 mg Lasmiditan matching placebo tablet and 1-100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
        </group>
        <group group_id="B2">
          <title>200 mg Lasmiditan</title>
          <description>Participants received 2-100 mg Lasmiditan tablets with 1-50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
        </group>
        <group group_id="B3">
          <title>Control</title>
          <description>Control 1: Participants received 1-50 mg Lasmiditan matching placebo tablet and 2-100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received 1-50 mg Lasmiditan tablet with 2-100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2: Participants received 1-50 mg Lasmiditan matching placebo tablet and 2-100 mg Lasmiditan matching placebo tablets to treat migraine attacks 1, 2 and 3.&#xD;
Participants received 1-50 mg Lasmiditan tablet and 2-100 mg Lasmiditan matching placebo tablets to treat migraine attack 4.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="485"/>
            <count group_id="B2" value="486"/>
            <count group_id="B3" value="500"/>
            <count group_id="B4" value="1471"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.90" spread="12.02"/>
                    <measurement group_id="B2" value="41.70" spread="11.95"/>
                    <measurement group_id="B3" value="40.60" spread="12.11"/>
                    <measurement group_id="B4" value="41.40" spread="12.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="418"/>
                    <measurement group_id="B3" value="416"/>
                    <measurement group_id="B4" value="1237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="135"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                    <measurement group_id="B2" value="390"/>
                    <measurement group_id="B3" value="401"/>
                    <measurement group_id="B4" value="1184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="80"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="72"/>
                    <measurement group_id="B3" value="78"/>
                    <measurement group_id="B4" value="221"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="370"/>
                    <measurement group_id="B2" value="368"/>
                    <measurement group_id="B3" value="379"/>
                    <measurement group_id="B4" value="1117"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Denmark</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="89"/>
                    <measurement group_id="B3" value="94"/>
                    <measurement group_id="B4" value="275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="164"/>
                    <measurement group_id="B2" value="162"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack</title>
        <description>Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an Intent-to-Treat (ITT) evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack</title>
          <description>Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an Intent-to-Treat (ITT) evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="29.3"/>
                    <measurement group_id="O3" value="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.83</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.56</ci_lower_limit>
            <ci_upper_limit>5.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.07</ci_lower_limit>
            <ci_upper_limit>6.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks</title>
        <description>To evaluate the 2 out of 3 primary consistency endpoint, the results of ITT evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT evaluable attacks, only the first 3 will be considered. Pain-free was defined as mild, moderate, or severe headache pain becoming none at the indicated assessment time.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who experienced at least 2 successes or 2 failures during their first 2 or 3 ITT evaluable attacks.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks</title>
          <description>To evaluate the 2 out of 3 primary consistency endpoint, the results of ITT evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT evaluable attacks, only the first 3 will be considered. Pain-free was defined as mild, moderate, or severe headache pain becoming none at the indicated assessment time.</description>
          <population>All randomized participants who experienced at least 2 successes or 2 failures during their first 2 or 3 ITT evaluable attacks.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="340"/>
                <count group_id="O2" value="336"/>
                <count group_id="O3" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4"/>
                    <measurement group_id="O2" value="24.4"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.10</ci_lower_limit>
            <ci_upper_limit>6.76</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.13</ci_lower_limit>
            <ci_upper_limit>12.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pain Relief at 2 Hours Post Dose During the First Attack</title>
        <description>Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who use at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Relief at 2 Hours Post Dose During the First Attack</title>
          <description>Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time.</description>
          <population>All randomized participants who use at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="65.2"/>
                    <measurement group_id="O3" value="41.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.71</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>3.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.04</ci_lower_limit>
            <ci_upper_limit>3.53</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 2 Out of 3 Attacks</title>
        <description>Headache pain relief is defined as a reduction in pain severity from moderate to severe at baseline to mild or none at 2 hours postdose in at least 2 out of 3 attacks. To evaluate at least 2 out of 3 consistency endpoints, the results of ITT-evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT-evaluable attacks, only the first 3 with the same treatment will be considered.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who experienced a sufficient number of successes or failures, (2 successes or 2 failures ) during their first 2 or 3 ITT-evaluable attacks.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 2 Out of 3 Attacks</title>
          <description>Headache pain relief is defined as a reduction in pain severity from moderate to severe at baseline to mild or none at 2 hours postdose in at least 2 out of 3 attacks. To evaluate at least 2 out of 3 consistency endpoints, the results of ITT-evaluable attacks in the lasmiditan 100-mg and 200-mg groups will be assessed, and the ITT-evaluable attacks treated with placebo in the control group will be used for comparison. For participants with more than 3 ITT-evaluable attacks, only the first 3 with the same treatment will be considered.</description>
          <population>All randomized participants who experienced a sufficient number of successes or failures, (2 successes or 2 failures ) during their first 2 or 3 ITT-evaluable attacks.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="332"/>
                <count group_id="O2" value="333"/>
                <count group_id="O3" value="320"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.91</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.11</ci_lower_limit>
            <ci_upper_limit>4.01</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.53</ci_lower_limit>
            <ci_upper_limit>4.85</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 24-Hour Sustained Pain Freedom During the First Attack</title>
        <description>Sustained pain freedom defined as pain free at 2 and 24 hours with no rescue medication.</description>
        <time_frame>24 Hours</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 24-Hour Sustained Pain Freedom During the First Attack</title>
          <description>Sustained pain freedom defined as pain free at 2 and 24 hours with no rescue medication.</description>
          <population>All randomized participants who received at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                    <measurement group_id="O2" value="17.3"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.52</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.05</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.67</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.77</ci_lower_limit>
            <ci_upper_limit>7.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With 48-Hour Sustained Pain Freedom During First Attack</title>
        <description>Sustained pain freedom defined as pain free at 2 and 48 hours with no rescue medication.</description>
        <time_frame>48 Hours Postdose</time_frame>
        <population>All randomized participants who received at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With 48-Hour Sustained Pain Freedom During First Attack</title>
          <description>Sustained pain freedom defined as pain free at 2 and 48 hours with no rescue medication.</description>
          <population>All randomized participants who received at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3"/>
                    <measurement group_id="O2" value="15.4"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.30</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.41</ci_lower_limit>
            <ci_upper_limit>6.94</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack in Triptan Insufficient Responders.</title>
        <description>Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack. A triptan insufficient responder is defined as having one of the following: 1) Scoring â‰¤5 on 4 questions from the Migraine Treatment Optimization Questionnaire (mTOQ-6) that defines participants with poor or very poor response to their current regimen; 2) Indicated they obtained pain freedom at 2 hours in 0 out of 3, or 1 out of 3 attacks when treated with the most recent triptan, or 3) are not currently taking triptan and discontinued their most recent triptan due to lack of efficacy, tolerability issue, or contradictions to a past triptan.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who were triptan insufficient responders and used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Pain Free 2 Hours Postdose During the First Attack in Triptan Insufficient Responders.</title>
          <description>Pain-free is defined as mild, moderate, or severe headache pain becoming none at 2 hours postdose during the first attack. A triptan insufficient responder is defined as having one of the following: 1) Scoring â‰¤5 on 4 questions from the Migraine Treatment Optimization Questionnaire (mTOQ-6) that defines participants with poor or very poor response to their current regimen; 2) Indicated they obtained pain freedom at 2 hours in 0 out of 3, or 1 out of 3 attacks when treated with the most recent triptan, or 3) are not currently taking triptan and discontinued their most recent triptan due to lack of efficacy, tolerability issue, or contradictions to a past triptan.</description>
          <population>All randomized participants who were triptan insufficient responders and used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="183"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0"/>
                    <measurement group_id="O2" value="25.6"/>
                    <measurement group_id="O3" value="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.80</ci_lower_limit>
            <ci_upper_limit>6.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.56</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.97</ci_lower_limit>
            <ci_upper_limit>6.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With no Disability as Measured by the Disability Item, at 2 Hours Postdose During the First Attack</title>
        <description>Percentage of participants with no disability as measured by the disability item, at 2 hours postdose during the first attack. Disability was measured by determining the level of interference with normal activities with 4 response options including not at all; mild interference, marked interference; and need complete bed rest.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With no Disability as Measured by the Disability Item, at 2 Hours Postdose During the First Attack</title>
          <description>Percentage of participants with no disability as measured by the disability item, at 2 hours postdose during the first attack. Disability was measured by determining the level of interference with normal activities with 4 response options including not at all; mild interference, marked interference; and need complete bed rest.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="19.8"/>
                    <measurement group_id="O3" value="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.48</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.65</ci_lower_limit>
            <ci_upper_limit>3.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks in Triptan Insufficient Responders</title>
        <description>Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at the indicated assessment time. A subject is not counted as being pain-free at a specific time point if she or he used rescue or recurrence medication at or before the specific time point.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who were triptan insufficient responders and experienced a sufficient number of successes or failures, (2 successes or 2 failures ) during their first 2 or 3 ITT-evaluable attacks.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 2 Out of 3 Attacks in Triptan Insufficient Responders</title>
          <description>Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe at baseline to none at the indicated assessment time. A subject is not counted as being pain-free at a specific time point if she or he used rescue or recurrence medication at or before the specific time point.</description>
          <population>All randomized participants who were triptan insufficient responders and experienced a sufficient number of successes or failures, (2 successes or 2 failures ) during their first 2 or 3 ITT-evaluable attacks.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="31"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="20.1"/>
                    <measurement group_id="O3" value="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.031</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>6.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.64</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.40</ci_lower_limit>
            <ci_upper_limit>13.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Free of Most Bothersome Symptom (MBS) Associated With Migraine at 2 Hours Postdose During the First Attack</title>
        <description>MBS freedom is defined as the absence of the associated symptom of migraine (nausea, phonophobia, or photophobia) at the indicated assessment time that was identified at baseline as the most bothersome symptom.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Free of Most Bothersome Symptom (MBS) Associated With Migraine at 2 Hours Postdose During the First Attack</title>
          <description>MBS freedom is defined as the absence of the associated symptom of migraine (nausea, phonophobia, or photophobia) at the indicated assessment time that was identified at baseline as the most bothersome symptom.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="376"/>
                <count group_id="O2" value="395"/>
                <count group_id="O3" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4"/>
                    <measurement group_id="O2" value="39.0"/>
                    <measurement group_id="O3" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.29</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.63</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.21</ci_lower_limit>
            <ci_upper_limit>2.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Requiring Rescue Medication for Migraine Within 24 Hours of Treatment During the First Attack</title>
        <description>Percentage of participants requiring rescue medication for migraine within 2 to 24 hours of treatment during the first attack</description>
        <time_frame>24 Hours</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Requiring Rescue Medication for Migraine Within 24 Hours of Treatment During the First Attack</title>
          <description>Percentage of participants requiring rescue medication for migraine within 2 to 24 hours of treatment during the first attack</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="311"/>
                <count group_id="O2" value="307"/>
                <count group_id="O3" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.6"/>
                    <measurement group_id="O2" value="19.2"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.33</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.30</ci_lower_limit>
            <ci_upper_limit>0.60</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Are Free of Symptoms Associated With Migraine at 2 Hours Postdose During the First Attack</title>
        <description>Percentage of participants that are free of symptoms associated with migraine (photophobia, phonophobia, nausea, and vomiting) at 2 hours postdose during the first attack.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Free of Symptoms Associated With Migraine at 2 Hours Postdose During the First Attack</title>
          <description>Percentage of participants that are free of symptoms associated with migraine (photophobia, phonophobia, nausea, and vomiting) at 2 hours postdose during the first attack.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.9"/>
                    <measurement group_id="O2" value="21.0"/>
                    <measurement group_id="O3" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.79</ci_lower_limit>
            <ci_upper_limit>4.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.20</ci_lower_limit>
            <ci_upper_limit>5.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Migraine Recurrence at 24 Hours During the First Attack</title>
        <description>Percentage of participants with migraine recurrence at 24 hours during the first attack defined as return of any headache in participants who were pain free at 2 hours.</description>
        <time_frame>24 Hours</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Migraine Recurrence at 24 Hours During the First Attack</title>
          <description>Percentage of participants with migraine recurrence at 24 hours during the first attack defined as return of any headache in participants who were pain free at 2 hours.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="127"/>
                <count group_id="O3" value="37"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.6"/>
                    <measurement group_id="O2" value="22.0"/>
                    <measurement group_id="O3" value="37.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pain Freedom, Pain Relief, Freedom From MBS, and No Disability Postdose During First Attack</title>
        <description>Percentage of participants with pain freedom, pain relief, freedom from MBS, and no disability postdose during first attack.</description>
        <time_frame>30 Minutes (Min) and 1 Hour (Hr) Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Freedom, Pain Relief, Freedom From MBS, and No Disability Postdose During First Attack</title>
          <description>Percentage of participants with pain freedom, pain relief, freedom from MBS, and no disability postdose during first attack.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain Freedom (30 Min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Freedom (1Hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Relief (30 Min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.6"/>
                    <measurement group_id="O2" value="22.4"/>
                    <measurement group_id="O3" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain Relief (1 Hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.7"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from MBS (30 Min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5"/>
                    <measurement group_id="O2" value="14.4"/>
                    <measurement group_id="O3" value="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Freedom from MBS (1 Hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.7"/>
                    <measurement group_id="O2" value="28.9"/>
                    <measurement group_id="O3" value="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Disability Postdose During First Attack (30 Min)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1"/>
                    <measurement group_id="O2" value="2.3"/>
                    <measurement group_id="O3" value="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Disability Postdose During First Attack (1 Hr)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0"/>
                    <measurement group_id="O2" value="9.9"/>
                    <measurement group_id="O3" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Freedom 30 Min. Postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.086</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>53.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Freedom 30 Min. Postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>59.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Free 1 Hour Postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>6.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Free 1 Hour Postdose</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>7.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>3.43</ci_lower_limit>
            <ci_upper_limit>14.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Relief 30 Min Postdose 100 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.065</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.98</ci_lower_limit>
            <ci_upper_limit>2.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Relief 30 Min. Postdose 200 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.25</ci_lower_limit>
            <ci_upper_limit>2.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Relief 1 Hour Postdose 100 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.74</ci_lower_limit>
            <ci_upper_limit>3.06</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Pain Relief 1 Hour Postdose 200 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.64</ci_lower_limit>
            <ci_upper_limit>2.88</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Freedom from MBS 30 Min 100 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.651</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Freedom from MBS 30 Min. 200 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.220</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Freedom from MBS 1 Hour 100 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.593</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.10</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Freedom from MBS 1 Hour 200 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.030</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.04</ci_lower_limit>
            <ci_upper_limit>1.98</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Total Score as Measured by the Migraine Disability Assessment Test (MIDAS) Scale</title>
        <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of 5 items that reflect the number of days reported as missed, or with reduced productivity at work or home and social events. Each question is answered as the number of days during the past 3 months of assessment, ranging from 0 to 90, with the total score being the summation of the 5 numeric responses. A higher value is indicative of more disability.</description>
        <time_frame>Baseline, Week 16</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Score as Measured by the Migraine Disability Assessment Test (MIDAS) Scale</title>
          <description>The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of 5 items that reflect the number of days reported as missed, or with reduced productivity at work or home and social events. Each question is answered as the number of days during the past 3 months of assessment, ranging from 0 to 90, with the total score being the summation of the 5 numeric responses. A higher value is indicative of more disability.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="447"/>
                <count group_id="O2" value="437"/>
                <count group_id="O3" value="451"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.7" spread="24.36"/>
                    <measurement group_id="O2" value="-12.0" spread="21.38"/>
                    <measurement group_id="O3" value="-13.1" spread="21.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.092</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.211</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Very Much or Much Better as Measured by Patient Global Impression of Change (PGI-C), at 2 Hours Postdose During the First Attack</title>
        <description>The PGI-C is a one-item questionnaire that asks participants to provide their impression of change since taking the medicine. The PGI-C is measured using a 7-point Likert scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Reported are participants whose combined impression of change since taking the medicine was very much better and much better at 2 hours postdose.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Very Much or Much Better as Measured by Patient Global Impression of Change (PGI-C), at 2 Hours Postdose During the First Attack</title>
          <description>The PGI-C is a one-item questionnaire that asks participants to provide their impression of change since taking the medicine. The PGI-C is measured using a 7-point Likert scale, with 1 = very much better, 2 = much better, 3 = a little better, 4 = no change, 5 = a little worse, 6 = much worse, and 7 = very much worse. Reported are participants whose combined impression of change since taking the medicine was very much better and much better at 2 hours postdose.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.8"/>
                    <measurement group_id="O2" value="30.0"/>
                    <measurement group_id="O3" value="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.85</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.01</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.12</ci_lower_limit>
            <ci_upper_limit>4.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Migraine Quality of Life Questionnaire (MQoLQ) Score at 24 Hours Post First Dose of Study During First Attack</title>
        <description>The 24-hour Migraine Quality of Life Questionnaire (24-hr MQoLQ) has been specifically developed to measure the HRQoL of participants with migraine within a 24-hour period after having taken migraine medication A domain score is calculated by summing the responses to the 3 questions and the domain score ranges from 3 to 21, with lower scores indicating less impairment. The questionnaire will be administered 24 hours after dosing with study drug during each migraine. The analysis of variance (ANOVA) model was used with region and treatment adjusted for the overall treatment effect.</description>
        <time_frame>24 Hours Post First Dose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Migraine Quality of Life Questionnaire (MQoLQ) Score at 24 Hours Post First Dose of Study During First Attack</title>
          <description>The 24-hour Migraine Quality of Life Questionnaire (24-hr MQoLQ) has been specifically developed to measure the HRQoL of participants with migraine within a 24-hour period after having taken migraine medication A domain score is calculated by summing the responses to the 3 questions and the domain score ranges from 3 to 21, with lower scores indicating less impairment. The questionnaire will be administered 24 hours after dosing with study drug during each migraine. The analysis of variance (ANOVA) model was used with region and treatment adjusted for the overall treatment effect.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="289"/>
                <count group_id="O2" value="303"/>
                <count group_id="O3" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Social Functioning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="4.8"/>
                    <measurement group_id="O2" value="12.1" spread="4.7"/>
                    <measurement group_id="O3" value="11.7" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Migraine Symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" spread="4.1"/>
                    <measurement group_id="O2" value="12.5" spread="4.2"/>
                    <measurement group_id="O3" value="11.4" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Feeling/Concern</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" spread="4.3"/>
                    <measurement group_id="O2" value="11.2" spread="4.5"/>
                    <measurement group_id="O3" value="10.3" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Social Functioning</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.267</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Migraine Symptoms 100 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.003</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Migraine Symptoms 200 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Feeling/Concerns 100 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.014</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Feelings/Concerns 200 mg</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Satisfied With Their Treatment Measured by a 4-Item Questionnaire</title>
        <description>Treatment satisfaction was evaluated at the End of Study (EoS) visit by determining the participant's level of satisfaction (ranging from extremely dissatisfied to extremely satisfied); their willingness to take this treatment again (ranging from strongly disagree to strongly agree) and if they would they recommend this treatment to another participants (ranging from strongly disagree to strongly agree).</description>
        <time_frame>Week 16</time_frame>
        <population>All randomized participants who use at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Satisfied With Their Treatment Measured by a 4-Item Questionnaire</title>
          <description>Treatment satisfaction was evaluated at the End of Study (EoS) visit by determining the participant's level of satisfaction (ranging from extremely dissatisfied to extremely satisfied); their willingness to take this treatment again (ranging from strongly disagree to strongly agree) and if they would they recommend this treatment to another participants (ranging from strongly disagree to strongly agree).</description>
          <population>All randomized participants who use at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="452"/>
                <count group_id="O2" value="444"/>
                <count group_id="O3" value="460"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Recommend Treatment - Agree/Strongly Agree</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="451"/>
                    <count group_id="O2" value="444"/>
                    <count group_id="O3" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.2"/>
                    <measurement group_id="O2" value="58.1"/>
                    <measurement group_id="O3" value="52.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Willing to Take Treatment - Agree/Strongly Agree</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="444"/>
                    <count group_id="O3" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.5"/>
                    <measurement group_id="O2" value="58.9"/>
                    <measurement group_id="O3" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Extremely/Very Satisfied/Satisfied with Medication</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                    <count group_id="O2" value="444"/>
                    <count group_id="O3" value="460"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.9"/>
                    <measurement group_id="O2" value="51.6"/>
                    <measurement group_id="O3" value="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prefer This Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="141"/>
                    <count group_id="O2" value="145"/>
                    <count group_id="O3" value="134"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.2"/>
                    <measurement group_id="O2" value="32.7"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Recommend Treatment - Agree Strongly Agree</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.101</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Recommend Treatment Agree/Strongly Agree</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.063</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.67</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Willing to Take This Treatment Again - Agree/Strongly Agree</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.376</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Willing to Take This Treatment Again - Agree/Strongly Agree</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.60</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Extremely/Very Satisfied</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.096</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.96</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Extremely/Very Satisfied</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.016</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.06</ci_lower_limit>
            <ci_upper_limit>1.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Prefer This Treatment</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.445</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.49</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.243</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Utility at 24 Hours Postdose as Measured by the EuroQol 5-Dimension 5-Level Scale (EQ-5D-5L) at 24 Hours Postdose During First Attack</title>
        <description>The EQ-5D-5L questionnaire is a participant-rated scale that assesses health status, it consists of 2 parts. The first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 possible levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems).The EQ-5D can be used to generate a health state index score, which is used to compute quality-adjusted life years for utilization in health economic analyses. The health state index score is calculated based on the responses to the 5 dimensions, providing a single value on a scale from less than 0 (where 0 is a health state equivalent to death) to 1 (perfect health), with higher scores indicating better health utility. ANCOVA was used to assess the effect of Lasmiditan over placebo or control. The model includes fixed categorical effect of treatment and geographic region and baseline as covariate.</description>
        <time_frame>Baseline, 24 Hours Postdose</time_frame>
        <population>All randomized participants who use at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Utility at 24 Hours Postdose as Measured by the EuroQol 5-Dimension 5-Level Scale (EQ-5D-5L) at 24 Hours Postdose During First Attack</title>
          <description>The EQ-5D-5L questionnaire is a participant-rated scale that assesses health status, it consists of 2 parts. The first part assesses 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) that have 5 possible levels of response (no problems, slight problems, moderate problems, severe problems, extreme problems).The EQ-5D can be used to generate a health state index score, which is used to compute quality-adjusted life years for utilization in health economic analyses. The health state index score is calculated based on the responses to the 5 dimensions, providing a single value on a scale from less than 0 (where 0 is a health state equivalent to death) to 1 (perfect health), with higher scores indicating better health utility. ANCOVA was used to assess the effect of Lasmiditan over placebo or control. The model includes fixed categorical effect of treatment and geographic region and baseline as covariate.</description>
          <population>All randomized participants who use at least 1 dose of study drug for an ITT evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2499" spread="0.25788"/>
                    <measurement group_id="O2" value="0.2270" spread="0.29854"/>
                    <measurement group_id="O3" value="0.2122" spread="0.25729"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.142</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 3 Out of 4 Attacks</title>
        <description>Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe to none at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who experienced a sufficient number of successes or failures, (3 out of 4 attacks) during ITT evaluable attacks for any of the consistency analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants That Are Pain Free at 2 Hours Postdose in at Least 3 Out of 4 Attacks</title>
          <description>Headache pain-free is defined as a reduction in pain severity from mild, moderate, or severe to none at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.</description>
          <population>All randomized participants who experienced a sufficient number of successes or failures, (3 out of 4 attacks) during ITT evaluable attacks for any of the consistency analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="325"/>
                <count group_id="O2" value="306"/>
                <count group_id="O3" value="387"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4"/>
                    <measurement group_id="O2" value="10.8"/>
                    <measurement group_id="O3" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.004</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.42</ci_lower_limit>
            <ci_upper_limit>6.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.22</ci_lower_limit>
            <ci_upper_limit>9.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 3 Out of 4 Attacks</title>
        <description>Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who experienced a sufficient number of successes or failures, (3 successes or 2 failures ) during ITT-evaluable attacks for any of the consistency analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Control</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Pain Relief at 2 Hours Postdose in at Least 3 Out of 4 Attacks</title>
          <description>Headache pain-relief is defined as a reduction in pain severity from moderate or severe at baseline to mild or none, or a reduction in pain severity from mild at baseline to none, at the indicated assessment time (2 hours postdose). To evaluate 3 out of 4 consistency endpoints; all ITT-evaluable attacks will be used. For the control group, the results of all ITT-evaluable attacks treated with lasmiditan 50 mg or placebo will be included. The control group is used for comparison. The population for 3 out of 4 consistency endpoints with sufficient number of successes or failures is defined as all participants who experienced at least 3 successes or 2 failures during ITT-evaluable attacks.</description>
          <population>All randomized participants who experienced a sufficient number of successes or failures, (3 successes or 2 failures ) during ITT-evaluable attacks for any of the consistency analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="260"/>
                <count group_id="O2" value="257"/>
                <count group_id="O3" value="317"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8"/>
                    <measurement group_id="O2" value="49.8"/>
                    <measurement group_id="O3" value="21.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.51</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.74</ci_lower_limit>
            <ci_upper_limit>3.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.50</ci_lower_limit>
            <ci_upper_limit>5.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Associated Migraines Symptoms of Nausea, Vomiting, Photophobia, and Phonophobia Present at 2 Hours Postdose for First Attack</title>
        <description>Presence of associated migraine symptoms at 2 hours postdose at first migraine attack, including each of the following: phonophobia, photophobia, nausea, and vomiting.</description>
        <time_frame>2 Hours Postdose</time_frame>
        <population>All randomized participants who used at least 1 dose of study drug for an Intent-to-Treat (ITT) evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
        <group_list>
          <group group_id="O1">
            <title>100 mg Lasmiditan</title>
            <description>Participants received one100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O2">
            <title>200 mg Lasmiditan</title>
            <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Control 1:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2:&#xD;
Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3.&#xD;
Participants received one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Associated Migraines Symptoms of Nausea, Vomiting, Photophobia, and Phonophobia Present at 2 Hours Postdose for First Attack</title>
          <description>Presence of associated migraine symptoms at 2 hours postdose at first migraine attack, including each of the following: phonophobia, photophobia, nausea, and vomiting.</description>
          <population>All randomized participants who used at least 1 dose of study drug for an Intent-to-Treat (ITT) evaluable attack, defined as a treated attack of at least mild pain severity with any postdose pain severity assessments at or before 2 hours postdose.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="419"/>
                <count group_id="O2" value="434"/>
                <count group_id="O3" value="443"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phonophobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.7"/>
                    <measurement group_id="O2" value="23.5"/>
                    <measurement group_id="O3" value="40.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Photophobia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.2"/>
                    <measurement group_id="O2" value="39.9"/>
                    <measurement group_id="O3" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="3.0"/>
                    <measurement group_id="O3" value="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nausea</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.953</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nausea</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.768</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Phonophobia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.39</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Phonophobia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Linear</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.34</ci_lower_limit>
            <ci_upper_limit>0.62</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Photophobia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.36</ci_lower_limit>
            <ci_upper_limit>0.63</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Photophobia</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Regression, Logistic</method>
            <param_type>Median Difference (Net)</param_type>
            <param_value>0.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.40</ci_lower_limit>
            <ci_upper_limit>0.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vomiting</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.129</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.17</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vomiting</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.769</p_value>
            <method>Regression, Logistic</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>2.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 4 months</time_frame>
      <desc>All randomized participants who take at least 1 dose of study drug, regardless of whether or not they undergo any study assessments. Gender specific events occurring only in male or female participants have had the number of participants At Risk adjusted accordingly.</desc>
      <group_list>
        <group group_id="E1">
          <title>100 Milligram (mg) Lasmiditan</title>
          <description>Participants received one 100 mg Lasmiditan tablet with one 50 mg Lasmiditan matching placebo tablet and one 100-mg Lasmiditan matching placebo tablet to maintain blind.</description>
        </group>
        <group group_id="E2">
          <title>200 mg Lasmiditan</title>
          <description>Participants received two 100 mg Lasmiditan tablets with one 50 mg Lasmiditan matching placebo tablet to maintain blind.</description>
        </group>
        <group group_id="E3">
          <title>Control</title>
          <description>Control 1 Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 4, and one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind, for migraine attack 3.&#xD;
Control 2 Participants received one 50 mg Lasmiditan matching placebo tablet and two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attacks 1, 2, and 3, and one 50 mg Lasmiditan tablet with two 100 mg Lasmiditan matching placebo tablets to maintain blind for migraine attack 4.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nasopharyngeal cancer stage iii</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hemiplegic migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Medication overuse headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sensory loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vestibular migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Heavy menstrual bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Intermenstrual bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tracheal mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="328" subjects_at_risk="485"/>
                <counts group_id="E2" subjects_affected="352" subjects_at_risk="486"/>
                <counts group_id="E3" subjects_affected="184" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="485"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Acute vestibular syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Deafness transitory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ear discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperacusis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="485"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="66" subjects_affected="44" subjects_at_risk="485"/>
                <counts group_id="E2" events="79" subjects_affected="47" subjects_at_risk="486"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal sensation in eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blepharospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Eye movement disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Eyelid ptosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Metamorphopsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pupillary reflex impaired</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="485"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="14" subjects_affected="11" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="485"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="485"/>
                <counts group_id="E2" events="15" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="65" subjects_affected="54" subjects_at_risk="485"/>
                <counts group_id="E2" events="103" subjects_affected="70" subjects_at_risk="486"/>
                <counts group_id="E3" events="34" subjects_affected="29" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="485"/>
                <counts group_id="E2" events="22" subjects_affected="18" subjects_at_risk="486"/>
                <counts group_id="E3" events="13" subjects_affected="11" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="22" subjects_at_risk="485"/>
                <counts group_id="E2" events="51" subjects_affected="30" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="485"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="75" subjects_affected="53" subjects_at_risk="485"/>
                <counts group_id="E2" events="106" subjects_affected="72" subjects_at_risk="486"/>
                <counts group_id="E3" events="21" subjects_affected="19" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="485"/>
                <counts group_id="E2" events="25" subjects_affected="19" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="9" subjects_affected="5" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeling drunk</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Feeling of relaxation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hunger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="485"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sensation of blood flow</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sensation of foreign body</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sense of oppression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="485"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Electrocardiogram t wave abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Intraocular pressure increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle strength abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pulse abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Total bile acids increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Food craving</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="12" subjects_affected="8" subjects_at_risk="485"/>
                <counts group_id="E2" events="11" subjects_affected="8" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="32" subjects_affected="22" subjects_at_risk="485"/>
                <counts group_id="E2" events="45" subjects_affected="29" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Allodynia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Altered state of consciousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="16" subjects_affected="10" subjects_at_risk="485"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Bradykinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Clumsiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="485"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="227" subjects_affected="154" subjects_at_risk="485"/>
                <counts group_id="E2" events="320" subjects_affected="182" subjects_at_risk="486"/>
                <counts group_id="E3" events="59" subjects_affected="44" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fine motor skill dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Formication</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="485"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="486"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="485"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="486"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="485"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mental impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Migraine with aura</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle contractions involuntary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Muscle spasticity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Myoclonus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="102" subjects_affected="70" subjects_at_risk="485"/>
                <counts group_id="E2" events="170" subjects_affected="93" subjects_at_risk="486"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Slow speech</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="47" subjects_affected="32" subjects_at_risk="485"/>
                <counts group_id="E2" events="82" subjects_affected="54" subjects_at_risk="486"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Taste disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tension headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="485"/>
                <counts group_id="E2" events="19" subjects_affected="12" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="485"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="485"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Attention deficit hyperactivity disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Derealisation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyssomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Emotional distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Fear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="7" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="485"/>
                <counts group_id="E2" events="20" subjects_affected="11" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="9" subjects_affected="6" subjects_at_risk="486"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Somatic symptom disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Chromaturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Renal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Erection increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="82"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="68"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="84"/>
              </event>
              <event>
                <sub_title>Intermenstrual bleeding</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Polymenorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="418"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="416"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="403"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="418"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="416"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sinonasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cold sweat</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="486"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Antibiotic prophylaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Tooth repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="485"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="486"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Peripheral coldness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Poor peripheral circulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="485"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
              <event>
                <sub_title>Raynaud's phenomenon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="485"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="486"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="500"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-595-5979</phone>
      <email>ClinicalTrials.gov@lilly.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

